Clarity that Creates Confidence

Bioarray’s mission is to enable cancer treatment decisions. The amount of data available to Patients, Oncologists and the entire care team can be overwhelming. We see it as our mission to use the very best tools available to simplify that data into clear answers that creates confidence in the decisions being made.

The BA-ER Quantification Test reduces the uncertainty in knowing if a patient has an Estrogen Receptor (ER) positive or ER-negative breast cancer. Using ER expression data, we can provide clarity between an ER-positive IHC & an ER-negative single-gene score.

The BA100 Triple Negative Breast Cancer Stratification Test will identify the approximately 67% of Triple Negative Breast Cancer Patients predicted not to achieve a complete response to the standard-of-care neoadjuvant chemotherapy. Using RNA expression data and a proprietary algorithm, we can provide an Oncologist with critical decision-making information early in the care pathway.